Remus Pharmaceuticals LimitedREMUSCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 6 quarters of data

₹1,011.55

MCap ₹1,192 Cr · P/E 25.6

Remus Pharmaceuticals Limited — Stock analysis & AI research Remus Pharmaceuticals Limited — Seasonality — best & worst months Remus Pharmaceuticals Limited — Technical indicators & charts Remus Pharmaceuticals Limited — Live exchange announcements

📋 Stocks Cheaper Than Their Industry 📋 Low Debt Stocks 📋 High Promoter Holding Stocks 🏭 Pharma sector

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹453 Cr

Sales · Mar 2026

+30.3% YoY

₹30 Cr

Operating Profit · Mar 2026

+22.3% YoY

6.6%

OPM % · Mar 2026

-7.0% YoY

₹25 Cr

Net Profit · Mar 2026

+21.5% YoY

₹16.54

EPS · Mar 2026

-52.6% YoY

📝 Remus Pharmaceuticals Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Remus Pharmaceuticals Limited reported revenue of ₹453 crore for the quarter ended March 2026 (Q4 FY26), up 30.3% from ₹348 crore in the same quarter last year.

Net profit rose 21.5% year-on-year to ₹25 crore, from ₹21 crore. Earnings per share (EPS) came in at ₹16.54.

Operating profit stood at ₹30 crore — an operating margin (OPM) of 6.6%, compared with 7.1% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹853 crore with a net profit of ₹47 crore.

Valuation snapshot

At the current price of ₹1,011.55, REMUS has a market capitalisation of ₹1,192 crore and a trailing P/E of about 25.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 22nd-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 70.95%, foreign institutional investors (FIIs) 5.28%, domestic institutional investors (DIIs) 0.83%, public shareholders 22.93% of Remus Pharmaceuticals Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

₹1,192 Cr

Current Price ?

₹1,011.5

P/E ?

25.59below ind

Industry P/E ?

37.20

P/B ?

3.40

P/S ?

1.40

P/FCF ?

298.00

Enterprise Value ?

₹1,219 Cr

EV/EBITDA ?

21.42

PEG ?

N/A

Earnings Yield ?

4.5%

Dividend Yield ?

0.10%

Profitability & Returns

Sales (TTM) ?

₹853 Cr

OPM ?

6.7%

Profit after tax (TTM) ?

₹47 Cr

EPS (TTM) ?

₹39.54

ROCE ?

17.0%

ROE ?

13.3%

ROA ?

8.0%

Growth

Sales — latest qtr ?

₹453 Cr

PAT — latest qtr ?

₹25 Cr

YoY qtr sales growth ?

30.3%

YoY qtr profit growth ?

21.5%

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹27 Cr

Debt to Equity ?

0.08

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

70.95%

Change in promoter holding ?

0.11%

Pledged percentage ?

N/A

Market

Return 3 months ?

37.8%

Return 6 months ?

58.5%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	29	183	38	348	400	453	+30.3%	—
Operating Profit	9	19	11	25	27	30	+22.3%	—
Other Income	2	4	2	3	3	4	+52.1%	—
Interest	0	0	0	1	1	1	+56.2%	—
Depreciation	0	0	0	1	1	1	-13.8%	—
Profit Before Tax	10	24	13	25	28	31	+22.3%	—
Net Profit	6	20	10	21	22	25	+21.5%	—
EPS	41.51	110.50	16.21	34.92	18.33	16.54	-52.6%	—
OPM %	31.9%	10.1%	29.0%	7.1%	6.7%	6.6%	-7.0%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 3 periods)

Metric	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	1	6	12	+100.0%
Reserves	156	250	339	+35.6%
Borrowings	14	23	27	+17.4%
Other Liabilities	161	154	201	+30.5%
Total Liabilities	333	433	579	+33.7%
Fixed Assets	14	16	18	+12.5%
CWIP	0	0	8	—
Investments	105	186	275	+47.8%
Other Assets	215	231	277	+19.9%
Total Assets	333	433	579	+33.7%

💧 Cash Flow (latest 3 periods)

Metric	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	1	7	18	+157.1%
Cash from Investing Activity	-25	-11	-15	-36.4%
Cash from Financing Activity	28	6	1	-83.3%
Net Cash Flow	4	3	5	+66.7%
Free Cash Flow	-11	3	4	+33.3%
CFO/OP	25%	32%	49%	+53.1%

➗ Ratios (latest 3 periods)

Metric	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	198	64	60	-6.2%
Inventory Days	96	35	35	+0.0%
Days Payable	209	49	37	-24.5%
Cash Conversion Cycle	85	50	58	+16.0%
Working Capital Days	98	54	57	+5.6%
ROCE %	—	20%	17%	-15.0%

👥 Shareholding (latest 4 periods)

Metric	Sep 2024	Mar 2025	Sep 2025	Mar 2026	% Chg
Promoters	70.84%	70.85%	70.91%	70.95%	+0.1%
FIIs	3.16%	4.77%	5.02%	5.28%	+5.2%
DIIs	0.77%	0.77%	0.77%	0.83%	+7.8%
Public	25.22%	23.60%	23.31%	22.93%	-1.6%
No. of Shareholders	1,753	1,878	2,032	2,009	-1.1%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →

#	Company	CMP	MCap (Cr)	P/E	Sales TTM	NP TTM	OPM%	NPM%	Sales YoY%	NP YoY%	Qtr Rev Δ%	Qtr NP Δ%
1	AKUMS Akums Drugs	₹784.55	12,012	41.2	4,502	293	12.6%	6.5%	5.9%	-25.5%	13.9%	56.1%
2	STAR Strides Pharma	₹1,085.00	10,001	26.7	3,636	389	25.4%	10.7%	-20.4%	99.0%	11.2%	50.0%
3	BLUEJET Blue Jet	₹565.05	9,802	36.9	884	265	36.3%	30.0%	8.0%	0.7%	-17.5%	-14.3%
4	AARTIPHARM Aarti Pharmalabs	₹828.30	7,511	36.1	1,957	208	22.0%	10.6%	1.5%	-26.9%	42.4%	39.2%
5	SUPRIYA Supriya Lifescience	₹870.30	7,004	35.3	873	198	33.2%	22.7%	18.9%	11.1%	30.8%	-30.9%
6	INNOVACAP Innova Captab	₹1,199.30	6,863	13.8	5,779	497	14.6%	8.6%	355.1%	277.4%	33.9%	42.3%
7	MOREPENLAB Morepen Laboratories	₹123.35	6,759	48.0	1,951	141	9.4%	7.2%	-0.3%	-18.3%	34.1%	394.0%
8	IOLCP IOL Chemicals	₹201.19	5,905	35.2	2,523	168	12.3%	6.7%	11.5%	36.6%	37.1%	89.8%
9	FDC FDC	₹350.20	5,702	19.5	2,191	291	15.3%	13.3%	3.0%	4.8%	3.0%	9.5%
10	NOVARTIND Novartis India	₹2,257.80	5,575	57.0	371	97	27.6%	26.2%	-0.3%	-6.9%	18.2%	14.3%
11	ORCHPHARMA Orchid Pharma	₹1,058.75	5,370	236.9	812	22	5.1%	2.7%	-11.9%	-76.4%	0.2%	25.4%
12	RPGLIFE RPG Life	₹2,865.90	4,740	39.7	735	120	21.1%	16.3%	8.4%	-36.9%	15.8%	16.3%
13	ZOTA Zota Health	₹1,232.70	4,269	—	609	-104	0.6%	-17.1%	84.6%	-29.8%	66.9%	-213.9%
14	GUFICBIO Gufic Biosciences	₹419.85	4,210	57.3	974	74	16.9%	7.6%	14.7%	-9.1%	14.9%	86.0%
15	UNICHEMLAB Unichem Laboratories	₹526.70	3,708	12.2	2,308	305	9.9%	13.2%	6.2%	74.1%	20.1%	496.1%
16	INDSWFTLAB Ind-Swift Laboratories	₹374.00	3,252	55.4	665	57	9.0%	8.6%	235.3%	10.1%	32.3%	-88.7%
17	ADVENZYMES Advanced Enzyme	₹293.25	3,249	19.8	750	172	29.8%	22.9%	17.1%	29.6%	2.1%	-4.6%
18	SOLARA Solara Active	₹667.00	3,218	85.6	1,535	37	15.2%	2.4%	6.6%	-1470.4%	33.1%	381.8%
19	DCAL Dishman Carbogen	₹162.08	2,541	157.6	2,902	16	16.7%	0.6%	8.1%	2655.7%	-4.3%	-351.7%
20	INDOCO Indoco Remedies	₹254.59	2,347	n/m	1,872	3	8.8%	0.2%	10.7%	-26.5%	6.5%	280.0%
21	PANACEABIO Panacea Biotec	₹368.55	2,257	—	673	-9	0.3%	-1.3%	14.4%	17.9%	19.7%	-44.4%
22	REMUS Remus Pharma.	₹1,911.30	2,252	91.1	94	25	31.7%	26.7%	—	—	13.3%	21.4%
23	SAKAR Sakar Healthcare	₹987.40	2,167	61.0	272	36	28.5%	13.3%	41.9%	71.8%	38.4%	120.2%
24	JAGSNPHARM Jagsonpal Pharmaceuticals	₹227.53	1,501	33.3	294	45	20.7%	15.4%	6.9%	-22.2%	8.5%	20.4%
25	KOPRAN Kopran	₹281.55	1,361	54.5	700	25	8.7%	3.6%	-96.0%	-97.6%	13.9%	-10.0%

❓ Frequently asked questions

What was Remus Pharmaceuticals Limited's revenue in Q4 FY26?